Acrivon Therapeutics Inc ACRV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACRV is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $8.47
- Day Range
- $8.20–8.78
- 52-Week Range
- $3.19–14.30
- Bid/Ask
- $8.42 / $8.60
- Market Cap
- $261.18 Mil
- Volume/Avg
- 276,495 / 810,213
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 61
- Website
- https://www.acrivon.com
Comparables
Valuation
|
Metric
|
ACRV
|
PRLD
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.57 | 0.94 | 0.76 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ACRV
PRLD
VOR
Financial Strength
|
Metric
|
ACRV
|
PRLD
|
VOR
|
|---|---|---|---|
Quick Ratio | 9.58 | 10.67 | 8.81 |
Current Ratio | 9.75 | 10.79 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
ACRV
PRLD
VOR
Profitability
|
Metric
|
ACRV
|
PRLD
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −30.45% | −38.93% | −41.83% |
Return on Equity (Normalized) | −32.98% | −43.41% | −51.69% |
Return on Invested Capital (Normalized) | −31.96% | −42.59% | −47.03% |
Return on Assets
ACRV
PRLD
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zxtjjjwntd | Xxyt | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Svzkdkv | Fcmyl | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hprkjwj | Qlrgg | $97.8 Bil | |
MRNA
| Moderna Inc | Npyqqdtg | Snzmk | $38.8 Bil | |
ARGX
| argenx SE ADR | Fxwshcrj | Dwnn | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Nqrzxks | Kqlh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cgvcrqwn | Gllsz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fjtjddf | Gbdcfxx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lszhqqvwvj | Fvndv | $12.5 Bil | |
INCY
| Incyte Corp | Tvjdrpcs | Sscvzqr | $11.6 Bil |